FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an <u>Bailey</u>	2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]									heck al	nship of Reportir I applicable) Director	,	Person(s) to Issuer  10% Owner							
(Last) (First) (Middle) 400 PROFESSIONAL DR, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 05/19/2016											Officer (give title pelow)	Other (specify below)			
(Street) GAITHERSBURG MD 20879 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)										ne) X	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,			Code (	Transaction Disposed Of (D) (II Code (Instr. 5)					5. Amount of Securities Beneficially Owned Following Reported		6. Ownersh Form: Direc (D) or Indire (I) (Instr. 4)	ect   of Inc ect   Bene   Owne	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	Tr	ansaction(s) nstr. 3 and 4)		(IIIsti	1. 4)	
Common Stock <sup>(1)</sup> 05/1						/2016		A		5,985 <sup>(2)</sup> A		A	\$(	)	34,485	D				
		Та	ıble II - C					•			sed of, onvertib				/ Owr	ied				
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date or Exercise (Month/Day/Year) if any		Date, (	Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration (Month/D	Date Expiration  Expiration Date  Month/Day/Year)  Date Expiration  Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amoun or Numbe of Title Shares		8. Price Derivat Securit (Instr. §	ive derivative Securities	Owners Form: Direct ( or Indir (I) (Inst	hip of Ind Bene D) Owne ect (Insti	Nature Idirect eficial Iership Ir. 4)		

## Explanation of Responses:

- 1. Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- $2. \ These \ restricted \ stock \ units \ vest \ annually \ in \ three \ equal \ installments \ beginning \ in \ May \ 2017.$

/s/Eric Burt, attorney-in-fact 05/23/2016

\*\* Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.